Project Details
Description
SPR001-205 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children Aged 6 to 17 Years with Congenital Adrenal Hyperplasia
| Status | Active |
|---|---|
| Effective start/end date | 7/12/21 → 9/30/26 |
Funding
- SPRUCE BIOSCIENCES, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.